8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Apr 17, 2026·SEC
Material company update
Apr 2, 2026·SEC
Avalon GloboCare Corp.(ALBT)Earnings, Financials & Key Ratios
ALBT•NASDAQ•REIT / Real Estate
Price updated Jun 19, 2026
AboutAvalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.Show more
- Revenue$0-100.0%
- FFO-$18M-138.1%
- FFO/Share-5.64+30.5%
- FFO Payout0%
- FFO per Share-5.64+30.5%
- ROE-223.61%-104.7%
- ROA-82.28%-116.4%
ALBT Key Insights
Avalon GloboCare Corp. (ALBT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗FFO declining 115.9% TTM
- ✗Weak momentum: RS Rating 5 (bottom 5%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ALBT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ALBT Price & Volume
Avalon GloboCare Corp. (ALBT) stock price & volume — 10-year historical chart
Loading chart...
ALBT Growth Metrics
Avalon GloboCare Corp. (ALBT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-125.56%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-116.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-33.01%
Return on Capital
10 Years-95.59%
5 Years-90.93%
3 Years-81.66%
Last Year-92.83%
ALBT Recent Earnings
Avalon GloboCare Corp. (ALBT) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.49
—
Rev
—
—
Q1 2026
Feb 13, 2026Metric
Actual
Est
EPS
$0.43
—
Rev
$1M
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.06
—
Rev
$350,099
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$2.02
—
Rev
$350,406
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.49 | — |
| Q1 2026 | Feb 13, 2026 | $0.43 | $1M |
| Q4 2025 | Nov 14, 2025 | $0.06 | $350,099 |
| Q3 2025 | Aug 14, 2025 | $2.02 | $350,406 |
Based on last 12 quarters of dataView full earnings history →
ALBT Peer Comparison
Avalon GloboCare Corp. (ALBT) competitors in Real estate owners and developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CELC | 4.28B | 87.76 | -23.22 | -244.61% | 1.94 | |||
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 SNGX | 4.12M | 0.40 | -0.19 | -246.04% | 0.07 | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 EDIT | 263.37M | 2.69 | -1.49 | 25.39% | -281.59% | -6.77% | 2.81 |
Compare ALBT vs Peers
Avalon GloboCare Corp. (ALBT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ALBT Income Statement
Avalon GloboCare Corp. (ALBT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.08M | 1.56M | 1.55M | 1.38M | 1.39M | 1.2M | 1.26M | 1.33M | 0 | -349.8K |
Revenue Growth % | 74.8% | 44.98% | -1.02% | -10.9% | 0.96% | -13.57% | 4.45% | 6.19% | -100% | -125.56% |
Property Operating Expenses | 829.79K | 1.17M | 1.21M | 987.56K | 976.45K | 929.44K | 1.02M | 1.07M | 158.83K | 299.17K |
Net Operating Income (NOI) | 247.76K▲ 0% | 388.01K▲ 56.6% | 339.91K▼ 12.4% | 390.2K▲ 14.8% | 414.52K▲ 6.2% | 272.73K▼ 34.2% | 238.19K▼ 12.7% | 267.83K▲ 12.4% | -158.83K▼ 159.3% | 430.12K▲ 0% |
NOI Margin % | 22.99% | 24.84% | 21.98% | 28.32% | 29.8% | 22.69% | 18.97% | 20.09% | - | -122.96% |
Operating Expenses | 2.78M | 7.96M | 19.72M | 12.84M | 9.25M | 9.07M | 15.99M | 5.2M | 7.59M | 9.51M |
G&A Expenses | 2.8M | 8.02M | 16.93M | 11.96M | 8.22M | 6.98M | 7.31M | 4.35M | 7.98M | 7.65M |
EBITDA | -3.7M | -7.11M | -18.87M | -12.08M | -8.4M | -8.33M | -15.42M | -4.63M | -7.43M | -9.48M |
EBITDA Margin % | -343.02% | -454.99% | -1220.36% | -876.46% | -603.54% | -692.63% | -1228.32% | -347.03% | - | 2710.32% |
Depreciation & Amortization | 181.64K | 522.84K | 506.74K | 378.48K | 438.78K | 466.28K | 329.95K | 300.47K | 158.83K | 675K |
D&A / Revenue % | 16.86% | 33.47% | 32.77% | 27.47% | 31.54% | 38.79% | 26.28% | 22.53% | - | -192.97% |
Operating Income | -3.88M▲ 0% | -7.63M▼ 96.8% | -19.38M▼ 153.9% | -12.45M▲ 35.7% | -8.83M▲ 29.1% | -8.79M▲ 0.5% | -15.75M▼ 79.2% | -4.93M▲ 68.7% | -7.59M▼ 54.1% | -10.16M▲ 0% |
Operating Margin % | -359.88% | -488.46% | -1253.13% | -903.93% | -635.08% | -731.42% | -1254.59% | -369.56% | - | 2903.29% |
Interest Expense | 138.11K | 314.65K | 608.33K | 168.76K | 200.48K | 3.58M | 1.35M | 2.44M | 1.46M | 1.35M |
Interest Coverage | -28.32x | -24.42x | -29.57x | -74.13x | -44.34x | -2.34x | -11.36x | -2.24x | -11.03x | - |
Non-Operating Income | 33.67K | 53.53K | -1.39M | 56.66K | 56.19K | -438.38K | -398.18K | 538.69K | 8.47M | 6.47M |
Pretax Income | -4.05M▲ 0% | -8.05M▼ 98.8% | -18.07M▼ 124.4% | -12.68M▲ 29.8% | -9.09M▲ 28.3% | -11.93M▼ 31.2% | -16.71M▼ 40.0% | -7.9M▲ 52.7% | -17.52M▼ 121.7% | -19.41M▲ 0% |
Pretax Margin % | -375.82% | -515.42% | -1168.6% | -920.29% | -653.54% | -992.44% | -1330.51% | -592.72% | - | 5549.87% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.46M▲ 0% | -7.77M▼ 124.4% | -18.07M▼ 132.4% | -12.68M▲ 29.8% | -9.09M▲ 28.3% | -11.93M▼ 31.2% | -16.71M▼ 40.0% | -7.9M▲ 52.7% | -18.26M▼ 131.1% | -19.52M▲ 0% |
Net Margin % | -321.5% | -497.61% | -1168.6% | -920.29% | -653.54% | -992.44% | -1330.51% | -592.72% | - | 5579.32% |
Net Income Growth % | -6332.86% | -124.41% | -132.44% | 29.83% | 28.31% | -31.25% | -40.03% | 52.69% | -131.05% | -116.42% |
Funds From Operations (FFO) | -3.28M▲ 0% | -7.25M▼ 120.9% | -17.56M▼ 142.2% | -12.3M▲ 30.0% | -8.65M▲ 29.7% | -11.46M▼ 32.5% | -16.38M▼ 42.8% | -7.6M▲ 53.6% | -18.1M▼ 138.1% | -18.84M▲ 0% |
FFO Margin % | -304.64% | -464.15% | -1135.83% | -892.82% | -621.99% | -953.66% | -1304.24% | -570.19% | - | 5386.35% |
FFO Growth % | -6003.3% | -120.9% | -142.21% | 29.96% | 29.67% | -32.51% | -42.85% | 53.58% | -138.09% | -475.53% |
FFO per Share | -0.50 | -1.01 | -2.34 | -1.55 | -1.02 | -1.23 | -1.56 | -8.12 | -5.64 | -2.10 |
FFO Payout Ratio % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
EPS (Diluted) | -0.53▲ 0% | -1.08▼ 103.8% | -2.41▼ 123.1% | -1.61▲ 33.2% | -1.09▲ 32.3% | -1.36▼ 24.8% | -1.59▼ 16.9% | -8.44▼ 430.8% | -5.64▲ 33.2% | -2.18▲ 0% |
EPS Growth % | -4962.39% | -103.77% | -123.15% | 33.2% | 32.3% | -24.77% | -16.91% | -430.82% | 33.18% | -33.01% |
EPS (Basic) | -0.53 | -1.08 | -2.41 | -1.61 | -1.09 | -1.36 | -1.59 | -8.44 | -5.64 | - |
Diluted Shares Outstanding | 6.5M | 7.2M | 7.51M | 7.95M | 8.49M | 9.33M | 10.53M | 936.61K | 3.21M | 8.96M |
ALBT Balance Sheet
Avalon GloboCare Corp. (ALBT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Assets | 12.67M | 13.4M | 10.49M | 10.37M | 10.24M | 19.75M | 20.58M | 20.99M | 23.4M | 16.25M |
Asset Growth % | 241.81% | 5.74% | -21.69% | -1.18% | -1.2% | 92.85% | 4.21% | 1.96% | 11.51% | -47.75% |
Real Estate & Other Assets | 25.32K | 7.88M | 7.83M | 7.94M | 374.76K | 16.74M | 7.47M | 7.09M | 6.94M | 0 |
PP&E (Net) | 48.03K | 249.56K | 601.42K | 616.45K | 506.85K | 149.18K | 166.33K | 17.62K | 727 | 153.92K |
Investment Securities | 1000K | 385.16K | 483.1K | 521.76K | 1000K | 485.01K | 1000K | 1000K | 0 | 0 |
Total Current Assets | 3.23M | 3.63M | 1.57M | 1.29M | 1.15M | 2.37M | 850.87K | 3.24M | 1.5M | 1.67M |
Cash & Equivalents | 3.03M | 2.25M | 764.89K | 726.58K | 807.54K | 1.99M | 285.4K | 2.86M | 109.09K | 776K |
Receivables | 48.65K | 52.22K | 243.89K | 35.4K | 90.87K | 134.63K | 234.66K | 122.96K | 758.94K | 478.52K |
Other Current Assets | 42.46K | 127.26K | 562.32K | 31.11K | 18.31K | 247.99K | 270.55K | 103.94K | 627.84K | 28.27K |
Intangible Assets | 1.58M | 1.26M | 0 | 0 | 0 | 0 | 0 | 0 | 2.16M | 1.61M |
Total Liabilities | 5.36M | 2.14M | 6.03M | 6.25M | 7.16M | 8.59M | 13.21M | 13.88M | 14.17M | 4.52M |
Total Debt | 1.5M | 1M | 3.19M | 3.73M | 3.3M | 4.57M | 8.64M | 7.84M | 6K | 1.42M |
Net Debt | -1.53M | -1.25M | 2.43M | 3.01M | 2.49M | 2.58M | 8.35M | 4.98M | -103.09K | 642.18K |
Long-Term Debt | 0 | 1M | 3.19M | 3.59M | 2.75M | 4.56M | 6.45M | 0 | 0 | 0 |
Short-Term Borrowings | 1.5M | 0 | 0 | 0 | 541.4K | 0 | 2.05M | 7.83M | 6K | 1.34M |
Capital Lease Obligations | 0 | 0 | 0 | 143.33K | 5.9K | 11.44K | 134.25K | 10.71K | 0 | 276.92K |
Total Current Liabilities | 5.36M | 1.14M | 2.84M | 2.59M | 4.4M | 3.58M | 6.76M | 13.88M | 14.15M | 4.44M |
Accounts Payable | 29 | 6.7K | 84.32K | 87.19K | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue | 12.77K | 28.96K | 0 | 23.51K | 8.64K | 27.68K | 11.43K | 38.35K | 0 | 0 |
Other Liabilities | 0 | 0 | 0 | 0 | 0 | 450K | 0 | 0 | 23.52K | 0 |
Total Equity | 7.31M▲ 0% | 11.25M▲ 54.0% | 4.47M▼ 60.3% | 4.12M▼ 7.8% | 3.08M▼ 25.1% | 11.16M▲ 261.8% | 7.37M▼ 34.0% | 7.1M▼ 3.6% | 9.23M▲ 30.0% | 11.72M▲ 0% |
Equity Growth % | 106.1% | 53.98% | -60.32% | -7.8% | -25.08% | 261.79% | -33.97% | -3.61% | 29.95% | -12.96% |
Shareholders Equity | 7.89M | 12.12M | 4.47M | 4.12M | 3.08M | 11.16M | 7.37M | 7.1M | 9.23M | 11.72M |
Minority Interest | -585.39K | -862.2K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Common Stock | 7.03K | 7.38K | 7.67K | 8.28K | 8.9K | 1K | 1.1K | 145 | 486 | 832 |
Additional Paid-in Capital | 11.49M | 24.15M | 34.59M | 46.86M | 54.89M | 65.95M | 67.89M | 72.02M | 88.38M | 96.07M |
Retained Earnings | -3.52M | -11.29M | -29.36M | -42.04M | -51.13M | -63.06M | -79.77M | -87.67M | -105.93M | -110.41M |
Preferred Stock | 0 | 0 | 0 | 0 | 0 | 9M | 20M | 23.5M | 27.54M | 26.82M |
Return on Assets (ROA) | -42.31% | -59.65% | -151.3% | -121.59% | -88.22% | -79.55% | -82.84% | -38.03% | -82.28% | -137.53% |
Return on Equity (ROE) | -63.83% | -83.76% | -229.91% | -295.49% | -252.47% | -167.53% | -180.35% | -109.23% | -223.61% | -835.03% |
Debt / Assets | 11.84% | 7.47% | 30.41% | 36.01% | 32.2% | 23.16% | 41.95% | 37.36% | 0.03% | 8.73% |
Debt / Equity | 0.21x | 0.09x | 0.71x | 0.91x | 1.07x | 0.41x | 1.17x | 1.10x | 0.00x | 0.12x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Book Value per Share | 1.12 | 1.56 | 0.59 | 0.52 | 0.36 | 1.20 | 0.70 | 7.58 | 2.87 | 1.31 |
ALBT Cash Flow Statement
Avalon GloboCare Corp. (ALBT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -1.34M | -4.4M | -7.08M | -7.55M | -5.02M | -7.04M | -6.5M | -4.97M | -4.99M | -6.4M |
Operating CF Growth % | -9680.18% | -228.14% | -61.05% | -6.59% | 33.42% | -40.06% | 7.57% | 23.61% | -0.38% | -33.49% |
Operating CF / Revenue % | -124.33% | -281.38% | -457.86% | -547.71% | -361.22% | -585.38% | -518.02% | -372.67% | - | 1828.23% |
Net Income | -4.05M | -8.05M | -18.07M | -12.68M | -9.09M | -11.93M | -16.71M | -7.9M | -17.52M | -19.52M |
Depreciation & Amortization | 181.64K | 522.84K | 506.74K | 378.48K | 438.78K | 466.28K | 329.95K | 300.47K | 158.83K | 675K |
Stock-Based Compensation | 993K | 3.09M | 9.21M | 5.49M | 2.11M | 1.11M | 1.18M | 521.51K | 1.82M | 1.05M |
Other Non-Cash Items | 1.32M | 52.97K | 1.39M | 7.55K | 17.31K | 3.11M | 8.73M | 3.34M | 8.87M | 10.98M |
Working Capital Changes | 213.98K | -12.51K | 1.64M | -856.21K | 1.5M | 206.89K | -35.07K | -1.23M | 1.68M | 310.2K |
Cash from Investing | -8.01M | -1.31M | -552.97K | -169.19K | -68.14K | -9.05M | -22.16K | -100K | 1.05M | 1.19M |
Acquisitions (Net) | 72.03K | -803.16K | -159.19K | -57.97K | -40.3K | -52K | 0 | -100K | 0 | 624.97K |
Purchase of Investments | -7.01M | -844.66K | -175.51K | -169.19K | 0 | -9.05M | 0 | 0 | 0 | 0 |
Sale of Investments | 0 | 0 | 175.51K | 0 | 0 | 9.05M | 0 | 0 | 14.5M | 561.46K |
Other Investing | -7.16M | -391.51K | -16.32K | 57.97K | -10.33K | -9M | 0 | 0 | -13.45M | 7.29K |
Cash from Financing | 9.5M | 5.04M | 6.15M | 7.66M | 5.17M | 17.26M | 4.83M | 7.64M | 1.4M | 4.72M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Common Dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debt Issuance (Net) | 1000K | -500K | 1000K | 400K | 1000K | 1000K | 1000K | -420.47K | 500K | 1.21M |
Share Repurchases | 0 | -522.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 2.85M | -1.49M | 0 | 0 | -240.43K | -290.52K | 74.95K | 1.7M | 125.32K | 1K |
Net Change in Cash | 140.84K▲ 0% | -774.75K▼ 650.1% | -1.49M▼ 92.0% | -38.31K▲ 97.4% | 80.96K▲ 311.3% | 1.18M▲ 1361.7% | -1.71M▼ 244.1% | 2.57M▲ 250.7% | -2.55M▼ 199.2% | -818.43K▲ 0% |
Exchange Rate Effect | -7.24K | -113.13K | -9.47K | 12.69K | 3.44K | 10.08K | -3.97K | 1.45K | -9.02K | -338.65K |
Cash at Beginning | 2.89M | 3.03M | 2.25M | 764.89K | 726.58K | 807.54K | 1.99M | 285.4K | 2.66M | 333.93K |
Cash at End | 3.03M | 2.25M | 764.89K | 726.58K | 807.54K | 1.99M | 285.4K | 2.86M | 109.09K | 776K |
Free Cash Flow | -2.27M▲ 0% | -4.51M▼ 98.7% | -7.46M▼ 65.4% | -7.55M▼ 1.2% | -5.04M▲ 33.2% | -7.04M▼ 39.6% | -6.53M▲ 7.3% | -4.97M▲ 23.9% | -4.99M▼ 0.4% | -6.4M▲ 0% |
FCF Growth % | -16727.04% | -98.68% | -65.38% | -1.19% | 33.18% | -39.61% | 7.28% | 23.87% | -0.38% | -13.88% |
FCF / Revenue % | -210.63% | -288.63% | -482.27% | -547.71% | -362.48% | -585.52% | -519.79% | -372.67% | - | 1828.23% |
ALBT Key Ratios
Avalon GloboCare Corp. (ALBT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
FFO per Share | -0.5 | -1.01 | -2.34 | -1.55 | -1.02 | -1.23 | -1.56 | -8.12 | -5.64 | -2.1 |
FFO Payout Ratio | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
NOI Margin | 22.99% | 24.84% | 21.98% | 28.32% | 29.8% | 22.69% | 18.97% | 20.09% | - | -122.96% |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.07x |
Debt / Assets | 11.84% | 7.47% | 30.41% | 36.01% | 32.2% | 23.16% | 41.95% | 37.36% | 0.03% | 8.73% |
Interest Coverage | -28.32x | -24.42x | -29.57x | -74.13x | -44.34x | -2.34x | -11.36x | -2.24x | -11.03x | - |
Book Value / Share | 1.12 | 1.56 | 0.59 | 0.52 | 0.36 | 1.2 | 0.7 | 7.58 | 2.87 | 1.31 |
Revenue Growth | 74.8% | 44.98% | -1.02% | -10.9% | 0.96% | -13.57% | 4.45% | 6.19% | -100% | -125.56% |
Related:ALBT Dividend History·ALBT Revenue History·ALBT Price History·ALBT P/E History·ALBT Financial Ratios·ALBT Institutional Holders
ALBT SEC Filings & Documents
Avalon GloboCare Corp. (ALBT) SEC filings — annual & quarterly reports (10-K, 10-Q)
ALBT Frequently Asked Questions
Avalon GloboCare Corp. (ALBT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Avalon GloboCare Corp. (ALBT) reported $-0.3M in revenue for fiscal year 2025.
Avalon GloboCare Corp. (ALBT) saw revenue decline by 100.0% over the past year.
Avalon GloboCare Corp. (ALBT) reported a net loss of $19.5M for fiscal year 2025.
Dividend & Returns
Avalon GloboCare Corp. (ALBT) has a return on equity (ROE) of -223.6%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Avalon GloboCare Corp. (ALBT) generated Funds From Operations (FFO) of $-18.8M in the trailing twelve months. FFO is the primary profitability metric for REITs.